Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer
This is a prospective, one-arm, phase II clinical study of Tislelizumab Combined With Anlotinib and Chemotherapy for Second-line Treatment of Advanced or Metastatic Pancreatic Cancer
Pancreatic Neoplasms
DRUG: Tislelizumab
MedianProgression free survival(mPFS), assessment by RECIST v1.1,at end of per 2 treatment cycles(each cycle is 21 days), from enrollment to disease progression or death from any cause, up to 24 months
objective response rate(ORR), assessment by RECIST v1.1,at end of per 2 treatment cycles(each cycle is 21 days), from enrollment to disease progression or death from any cause,up to 24 months|Median Overall Survival, document and assessment on baseline, at end of 2 treatment cycles(each cycle is 21 days）, from enrollment to death from any cause,up to 24 months|disease control rate(DCR), document and assessment on baseline, at end of 2 treatment cycles(each cycle is 21 days）, up to 24 months
This is a single-arm, open-label, clinical trial of tislelizumab in combination with anlotinib and investigator-selected chemotherapy for second-line treatment of patients with advanced or metastatic pancreatic cancer. Patients with histopathologically or cytologically confirmed unresectable, recurrent or metastatic pancreatic cancer are planned to be recruited. Systemic medical antineoplastic therapy previously treated with first-line chemotherapy, meeting the inclusion and exclusion criteria of this study, and giving tislelizumab and anlotinib in combination with investigator 's choice of second-line chemotherapy regimen